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ABSTRACT Fc receptor–antibody interactions are key mechanisms through which antibody effector functions are mediated.
Neutrophils coexpress two low-affinity Fc receptors, CD16b (FcRIIIb) and CD32a (FcRIIa), possessing overlapping ligand
binding specificities but distinct membrane anchor and signaling capacities. Using K562 cell transfectants as a model, the
kinetics of both separate and concurrent binding of CD16b and CD32a to surface-bound IgG ligands were studied. CD16b
bound human IgG with 2–3 times higher affinity than did CD32a (AcKa  4.1 and 1.6  10
7 m4, respectively) and both
FcRs had similar reverse kinetic rates (kr  0.5 and 0.4 s
1, respectively). Because CD16b is expressed on neutrophils at
a 4–5 times higher density than CD32a, our results suggest that CD16b plays the dominant role in binding of neutrophils to
immobilized IgG. The question of possible cross-regulation of binding affinity between CD16b and CD32a was investigated
using our multispecies concurrent binding model (Zhu and Williams, Biophys. J. 79:1850–1857, 2000). Because the model
assumes independent binding (no cooperation among different species), the excellent agreement between the model
predictions and the experimental data suggests that, when coexpressed on K562 cells, these two FcRs do not interact in
a manner that alters the kinetic rates of either molecule.
INTRODUCTION
Human neutrophils, which comprise over 70% of all circu-
lating leukocytes, constitutively express two low-affinity
FcRs at resting state, FcRIIa (CD32a) and FcRIIIb
(CD16b) (Salmon et al., 1996). Binding to antigen-com-
plexed IgG brings about the cross-linking of FcRs, which
trigger a wide variety of immune responses. These may
include clearance of immune complex, antibody-dependent
cell-mediated cytotoxicity, phagocytosis, release of inflam-
matory mediators, and regulation of lymphocyte prolifera-
tion and differentiation (van de Winkel and Capel, 1996;
Fridman and Sautes, 1997). As such, the knowledge of
FcR–IgG interactions is fundamental to the understanding
of inflammatory processes and body defense by the immune
system.
CD32a and CD16bNA2 are the subjects of the present
study. CD32, a 40-kDa protein, is the most widely distrib-
uted Fc receptor. It has an extracellular portion that consists
of two Ig-like domains, a single-span polypeptide trans-
membrane segment, and a cytoplasmic domain that contains
an immunoreceptor tyrosine-based activator motif. Two al-
lotypes of CD32a are known and are characterized by either
an arginine or histidine residue at amino acid position 131.
About 50% of Caucasians and 40% of Asians heterozygously
express both CD32aR131 and CD32aH131 (Rascu et al., 1997),
a mix we collectively denote herein as CD32aR/H131. CD16b, a
50–70-kDa glycoprotein, is the predominant Fc receptor in
blood, and is only expressed on neutrophils. It has an ectodo-
main that shares a high degree of homology with CD32a.
However, it lacks the transmembrane and cytoplasmic do-
mains, and anchors to the cell surface by means of a glycosyl
phosphatidylinositol moiety. Like CD32a, two allotypes of
CD16b exist, denoted NA1 and NA2 (Edberg et al., 1989;
Ravetch and Perussia, 1989; Scallon et al., 1989; Selvaraj et
al., 1988, 1989) (Fig. 1).
The biological significance of coexpressing two FcRs
with overlapping ligand-binding specificity (but distinct
membrane anchors and signaling capacities) is not fully
understood. It has been suggested that CD16b and CD32a
may have distinct functional roles, can be differentially
regulated, and may cooperatively interact (Selvaraj et al.,
1989; Edberg and Kimberly, 1994; Edberg et al., 1998). The
density of CD16b expressed on neutrophils is 4–5 times
higher than that of CD32a (135,000 vs. 31,000 mol/cell)
(Selvaraj et al., 1988). In addition, CD16b binds immobi-
lized IgG with a nearly threefold higher affinity than CD32a
(this study). Thus, CD16b should be the primary FcR that
neutrophils use to engage in initial binding. These two
FcRs also differ in their signaling capacities. Cross-linking
of neutrophil CD32a induces degranulation, Ca2 mobili-
zation, erythrocyte cytotoxicity, tumor cell cytotoxicity, re-
spiratory burst, and phagocytosis. Under similar conditions,
neutrophil CD16b is capable of delivering signals for the
former three but not for the latter three FcR-dependent
functions (Perussia et al., 1983; Shen et al., 1987; Lanier et
al., 1988; Fanger et al., 1989; Selvaraj et al., 1989; Huizinga
et al., 1990; Kimberly et al., 1990; Naziruddin et al., 1992).
These data show that CD32a is a more potent trigger mol-
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ecule than CD16b. It has been suggested that CD16b sig-
naling may be cross-regulated by CD32a (Naziruddin et al.,
1992; Edberg and Kimberly, 1994), but it is not known
whether such interaction includes affinity modulations. The
affinity state of neutrophil CD32a has been found to be
upregulated by activation of neutrophils with a bacterial
chemotactic peptide, fMLP. With the same treatment, how-
ever, CD16b is shed from the neutrophil surface (Nagarajan
et al., 2000).
To examine whether the suggested cross-regulation of
CD16b and CD32a occurs at the level of affinity modula-
tion, in the present paper, we measured the kinetics and
equilibrium binding of these two FcRs using the micropi-
pette binding frequency assay. The experiments used, as a
model for neutrophils, a human erythroleukemia K562 cell
line that natively expressed CD32aR/H131 (Warmerdam et
al., 1990) and was transfected to express CD16bNA2 at a
ratio similar to that on neutrophils. Micropipette adhesion
frequency experiments were performed, using human red
blood cells (RBC) to present membrane-bound IgG ligands.
To examine the two FcRs separately, adhesion-blocking
monoclonal antibodies (mAb) were used to sequentially
inhibit the function of each unwanted receptor. Experiments
were also performed in the absence of any blocking mAb to
allow concurrent binding of both FcRs to cell-bound IgG.
The single-receptor binding data obtained in the blocking
experiments were analyzed using the single-species adhe-
sion model of Chesla et al. (1998). The estimated kinetic
rate and binding affinity constants were then used as input
to a multiple-species model (Zhu and Williams, 2000) to
predict the concurrent binding of CD16b and CD32a in the
nonblocked experiments. Just as with the multiple ligand
cases presented in Williams et al. (2000), the multiple
receptor data corresponded quite well with the 95% predic-
tion intervals generated in this manner, providing additional
support for the multispecies theory.
One of the underpinning assumptions of these adhesion
models is that the formation (and dissociation) of each
discrete bond is independent of any others. This precludes
competition or adhesion-dependent affinity regulation be-
tween or among receptor and ligand species. Therefore, the
excellent agreement between the prediction and the data
suggests that, when CD16bNA2 and CD32aR/H131 are coex-
pressed on K562 cells, the binding of a soluble blocking
mAb or immobilized ligand to either receptor does not alter
the kinetic rates of the other.
MATERIALS AND METHODS
Antibodies and cells
The monoclonal antibodies CLBFcgran1 (anti-CD16, mIgG2a), 3G8 (anti-
CD16, mIgG1), IV.3 (anti-CD32, mIgG2b), TS2/9 (anti-CD58, mIgG1),
and X63 (no known human antigen, mIgG1) were purified in-house from
hybridoma culture supernatant by protein G affinity chromatography, as
previously described (Selvaraj et al., 1988; Nagarajan et al. 2000). Fab
fragments of CLBFcgran1 and IV.3 were cleaved by Lampire (Pipersville,
PA). Murine mAb GG7 (anti-human IgG Fc) was obtained as ascites fluid
from Sigma Chemical Company (St. Louis, MO). Other negative control
murine mAbs with no known human antigens obtained from Sigma in-
cluded UPC-10 (mIgG2a) and MOPC-141 (mIgG2b). The goat anti-mouse
FITC-conjugated polyclonal antibody used for flow cytometry was also
from Sigma and the total serum human IgG used as ligand for FcRs was
from Lampire.
The human erythroleukemia K562 cell line was from American Type
Cell Culture (Rockville, MD). Transfectant K562 cells expressing
CD16bNA2 were established by cotransfecting a pCDM8 vector containing
the CD16bNA2 gene and a pSV vector containing a hygromycin gene. We
have previously described a similar transfection with these genes into CHO
cells (Nagarajan et al., 1995). Transfected cells were selected with 400
g/ml hygromycin and maintained in RPMI 1640 media plus 10% FCS
containing 200 g/ml of hygromycin. The cell density in the culture was
no higher than 5  105 cells/ml. Human RBCs were isolated from whole
blood of normal healthy volunteers as described in Williams et al. (2000).
Chromium chloride coupling of IgG and
determination of receptor and ligand densities
Human IgG (or IgG-free ovalbumin) was covalently coupled to the mem-
branes of RBCs by means of a chromium chloride (CrCl3) method (Kofler
and Wick, 1977). Site densities of IgG on RBC surfaces were determined
by quantitative indirect fluorescent immunoassay using CD58 expression
as a reference. The expression of CD16b and CD32a on the transfected and
nontransfected K562 cells was observed by flow cytometry to be stable
under the culture conditions described earlier. Receptor site density was
quantified by radioimmunoassay using 125I-labeled Fab fragments against
CD16 (CLBFcgran1) or CD32 (IV.3). Detailed procedures have been
presented in Williams et al. (2000).
Micropipette binding-frequency assay
Healthy cells of similar, roughly average size were individually selected by
micropipette for subsequent adhesion testing. The micropipette system and
the binding-frequency assay have been described in detail previously
(Chesla et al., 1998, also see Williams et al., 2000). In essence, the assay
measures an adhesive chemical reaction mechanically, because the prod-
ucts of the reaction are bonds that physically link the ligand-presenting
FIGURE 1 Schematics of the glycosyl phosphatidylinositol (GPI)-an-
chored CD16b and the polypeptide-anchored CD32a molecules. The Ig-
like domains are depicted as globules. The immunoreceptor tyrosine-based
activator motif (ITAM) is also shown.
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RBC to the receptor-expressing K562 cell. A micropipette-aspirated RBC
picoforce transducer is used to detect adhesion, not to measure adhesion
force; the quantity of interest is adhesion probability, not adhesion strength.
Adhesion probability is estimated from the frequency of adhesion events
observed in a large number of repeated cell–cell contacts, controlled by
micromanipulation. The kinetic rate and equilibrium affinity constants are
extracted from the dependence of the adhesion probability on contact
duration, along with the independently measured receptor and ligand
densities.
For the parameter evaluation to work well, the receptor and ligand
densities should be adjusted in accordance with the binding affinity such
that the adhesion probability data are in the mid ranges. A high-affinity
interaction that results in an adhesion probability of nearly 100% cannot be
easily distinguished from an interaction of twice that affinity. Similarly, it
is difficult to distinguish a low-affinity interaction that yields a low
adhesion probability (e.g., 10%) from one of half that affinity. Both data
before and including steady state are important, because the equilibrium
binding affinity is related to the maximum (steady-state) adhesion fre-
quency and the reverse kinetic rate is related to the time required to achieve
a half-maximal adhesion frequency. It is therefore difficult to apply the
assay to slow reactions, because the requirement for measuring adhesion
probability through repeated contacts becomes prohibitive when each
contact duration is long. Finally, the molecular system should be such that
no appreciable depletion (or enhancement) of functionality occurs during
the repeated tests. Gradual declines (or inclines) in adhesion frequency
during the course of repeated tests can render error in the adhesion
probability estimates. All of the above requirements were satisfied in our
system of CD16b-transfected K562 cells and IgG-coated RBCs.
Data analysis
Kinetic rate and equilibrium affinity constants were extracted from the
binding frequency data by iteratively reweighted nonlinear regression to
the concurrent binding model (see Eq. 2) using the Levenberg–Marquardt
algorithm (Wolfram Research, 1996). After analysis of the blocked data,
prediction intervals (with 95% confidence levels) were computed for the
expected mean response of the nonblocked experiments, assuming the
validity of the concurrent binding model. Details of the weighting method
and the prediction interval calculation are presented in Williams et al.
(2000). Briefly, the micropipette data exhibit heteroscedasticity, or heter-
ogeneity of variance, that needs to be corrected to obtain appropriate
best-fit parameters, their standard errors, and prediction intervals. The
reciprocal of the estimated variance was used as a weighting function in the
nonlinear regression problem. A model was constructed for the variance of
the adhesion probability based on its dependence on the variation in the
receptor and ligand densities in the cell population. Determination of
weights that best equalized the variance across the entire range of response
required iteration. Once the single-species (blocked), iteratively re-
weighted, nonlinear least-squares problem was iterated to convergence, the
regression parameter vector and the asymptotic covariance matrix were
used to calculate the prediction intervals for the mean response under
dual-species (nonblocked) conditions, following standard procedures (e.g.,
see Jennrich, 1995, Chapter 8).
RESULTS
CD16b is the dominant Fc receptor on
CD16b-transfected K562 cells
As shown in Fig. 2, nontransfected K562 cells expressed
CD32a but not CD16b, whereas the transfected cells ex-
pressed both CD16b and CD32a. The expression levels,
quantified by radioimmunoassay, were 1.9  106 CD16b
and 0.5  106 CD32a per K562 cell. To calculate expres-
sion density, the mean surface area of the K562 cells was
determined from digital video micrography of over 100
healthy cells, yielding a mean apparent surface area of 584 
13m2 SEM. The derived site densities were 3250 CD16b and
860 CD32a per m2. Along with IgG coating densities of
35–650 perm2, this provided an excess of available receptors
and ligands relative to the anticipated number of bonds in the
contact area, ensuring that the effects of competition would be
negligible (Zhu and Williams, 2000).
Adhesion of K562 transfectants to IgG-coated
RBCs was due to specific FcR binding
The single-species binding model used in previous studies
(Piper et al., 1998; Chesla et al., 1998) has been extended to
include multispecies concurrent binding in Zhu and Williams
(2000). When binding is independent, the probability of spe-





FIGURE 2 Fluorescence histogram of nontransfected (left column) and
CD16bNA2-transfected (right column) K562 cells. Cells were stained for
flow cytometry using either anti-CD16 (3G8, middle row), anti-CD32
(IV.3, bottom row), or an irrelevant (X63, top row) murine mAb. The
secondary antibody was a FITC-conjugated goat anti-mouse IgG poly-
clonal Ab.
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is the average number of bonds formed by either CD16b
(denoted by subscript 1) or CD32a (denoted by subscript 2).
mr and m are the respective surface densities of the recep-
tors and ligands. Ka is the two dimensional (2D) equilibrium
binding affinity, and kr is the reverse rate. t and Ac are
contact duration and area, respectively. Retaining only a
single ni	 term in Eq. 1 reduces it to the single-species
model (Chesla et al., 1998). These adhesion probability
models are readily applied to dual-micropipette assays.
Micropipette binding-frequency assays were performed
using IgG-coated RBCs to repeatedly contact CD16b-trans-
fected K562 cells preincubated with either adhesion-block-
ing mAbs against one or both of the FcRs or isotype-
matched irrelevant control mAb (all at 10 g/ml
concentration), or without any antibody. The adhesion fre-
quency versus contact time data was fit to the single-species
version of Eq. 1 to extract an mrAcKa value for each con-
dition. When only a single-receptor species was present
(Fig. 3 A), this parameter was the equilibrium average num-
ber of bonds per unit density of IgG ligand. (Note that these
bond averages are over all contacts, not just those that
resulted in adhesion.) When both FcRs were present (Fig.
3 B), the single-species model yielded the homogenized
receptor approximation to the dual-receptor binding (Zhu
and Williams, 2000). The fitted parameter mrAcKa¯ therefore
approximated the equilibrium average number of total
bonds per unit density of IgG ligand, mr1AcKa1 . The results
in Fig. 3 show that the mrAcKa (or mrAcKa¯) value was
reduced by treatment of anti-CD16 (CLBFcgran1, mIgG2a)
and anti-CD32 (IV.3, mIgG2b) mAbs but not by treatment
of irrelevant mAbs, regardless of isotype. Blocking with
whole Ab produced comparable results to those produced
with cleaved Fab fragments. These data demonstrate the
specificity of the adhesion probabilities measured in the
micropipette experiments. It is also evident that, on average,
CD16b contributed much more to the formation of FcR-
IgG bonds in this system than did CD32a when the other
receptor was blocked by mAb. This suggests that, relative to
CD16b, CD32a may have a lower 2D affinity for IgG in
addition to the lower expression level discussed earlier. This
suggestion was confirmed in subsequent analysis, detailed
later.
Receptor blocking experiments follow the
prediction of the single-species model
Data from all receptor-blocking experiments are shown in
Fig. 4. To increase the reliability of the estimated binding
parameters and the power of statistical inference in the
prediction interval calculation, two preparations of IgG-
coated RBCs (m  580 and 650 IgG/m
2) were used for
each blocking condition. CLBFcgran1 (anti-CD16 mAb)
blocked most of the binding by itself (Fig. 4 B), though IV.3
(anti-CD32 mAb) had a clearly discernible effect when
added alone (cf. Fig. 4 A with Fig. 6, A and B) or together
with CLBFcgran1 (Fig. 4 C). When the RBCs were coated
with IgG-free ovalbumin instead of IgG, the nonspecific
binding to the transfectant K562 cells was similar to that of
the double-blocking experiment with both IV.3 and CLB-
Fcgran1 present (Fig. 4 D).
By adding an empirical expression describing the proba-
FIGURE 3 (A) Anti-FcR mAb blocking and (B) isotype-matched irrel-
evant mAb control experiments. Soluble Fab and whole forms of anti-
CD16 (CLBFcgran1, mIgG2a) and anti-CD32 (IV.3, mIgG2b) mAbs, as
well as whole irrelevant mAbs of various isotypes, were tested alone or in
combination for their ability to block binding of CD16b-transfected K562
cells to IgG-coated RBCs in the micropipette assay. Adhesion frequency
data so obtained was analyzed by the single-species version of Eq. 1, and
the resulting values for the mean number of bonds present at equilibrium
per unit density of IgG are shown. N  5 cell pairs, each at a different
contact time, with 100 contact cycles each. Ligand densities were 35–650
IgG/m2. Error bars represent standard errors on the estimated means.
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bility of nonspecific adhesion to the model for PS given in
Eq. 1, the following general model for the total probability
of adhesion is obtained (Zhu and Williams, 2000):




This can then be used to simultaneously fit both the non-
specific binding (characterized by parameters a and b) and
the specific adhesions that are mediated by N ( 2 for the
present case) species of receptor–ligand bonds. Here we
have also provided an element to account for the presence of
blocking agents. i is the blocking score, and it is defined to
be equal to 1 if the ith receptor species is blocked and 0 if
it is not blocked. i is the blocking efficiency of the mAb
against the ith receptor species.
For the purpose of model testing, we neglected any block-
ing inefficiency. A single set of binding constants was
determined by fitting all blocking data shown, as well as the
nonspecific data, to Eq. 2, assuming i  1 (i.e., complete
blocking) for both IV.3 and CLBFcgran1. The four binding
parameters so determined are listed in Table 1 and form the
basis for the curves shown in Fig. 4 (and the prediction
intervals of Fig. 6, discussed below).
Blocking is nearly complete
If the inhibitory antibodies, at the concentrations used (10
g/ml), were able to block all target receptors perfectly,
then adding both antibodies would completely eliminate
specific binding. The remaining binding would be entirely
nonspecific and would therefore be independent of the
ligand density used. Similarly, removal of the ligand by
replacement with IgG-free ovalbumin would leave only
nonspecific binding. Therefore, in the preceding section, the
data in Fig. 4 C (no available receptors) and Fig. 4 D (no
ligands) were treated as equivalent under the complete
blocking assumption, and a single curve was generated to fit
both sets. It is apparent, however, that the combined use of
both blocking antibodies was still insufficient to inhibit all
FIGURE 4 Binding curves from receptor blocking experiments. (A–C) One or both of the Fc receptors were blocked from participation in binding to
human IgG-coated RBCs by pre-incubating the transfectant K562 cells with the indicated antibody or antibodies (10 g/ml, 30 min) and conducting
micropipette binding frequency assays in the continuous presence of the antibody or antibodies (2 g/ml). (D) An additional experiment was performed
with nonblocked transfectant K562 cells binding to IgG-free ovalbumin-coated RBCs. Each point represents total adhesion probability estimated from one
cell pair with 100 contact cycles. Curves are derived from the best-fit kinetics parameters obtained from applying the concurrent binding model (Eq. 2) to
all blocking data simultaneously, treating the data in (A) as CD16b only, (B) as CD32a only, and (C and D) as nonspecific binding. IgG site densities were
580 m2 (E, dotted curves) or 650 m2 (F, solid curves).
TABLE 1 Summary of binding parameters for total human IgG
Data Set
AcKa (10
7 m4) kr (s
1)
¯CD16bNA2 CD32aR/H131 CD16bNA2 CD32aR/H131
Blocking data only 3.7  0.3 1.8  0.4 0.50  0.10 0.43  0.24 (1)
All data,  fixed 3.9  0.2 1.9  0.1 0.49  0.06 0.43  0.21 (1)
All data,  free 4.1  0.2 1.6  0.4 0.50  0.06 0.38  0.18 0.94
N  44 and 81 cell pairs (100 contact cycles each) for blocking and all data, respectively. An additional 10 cell pairs were used to characterize the
nonspecific binding.
Values are mean  SE.
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specific binding, indicating that a detectable number of
receptors were not blocked by the antibodies. Using Eq. 2,
the mean blocking efficiency  was estimated during the
fitting of the data to be 94%  3%. (The data would have
to be exceptionally tight and numerous to allow separate
determination of i for each antibody, so it was necessary to
presume that the antibodies behaved similarly in this re-
gard.) During the regression, this parameter was free to take
on any value, so its best-fit level near unity was a good
indication that the blocking efficiency was nearly perfect at
the concentrations used.
Use of this slightly incomplete blocking efficiency value
of 94% results in a small shift in the extracted parameters
and the curves generated by them. Dual-block experiments
are no longer expected to match the no IgG curves, and are
also ligand-density dependent. Figure 5 illustrates the im-
provement of the fit for these conditions when incomplete
blocking is accommodated. The curves in Fig. 4, A and B,
are minimally shifted (not shown). Still, although this
method does provide a reasonable blocking efficiency esti-
mate, addition of another free parameter to the model under
evaluation might compromise the rigor of the predictive
test. For this reason, we chose to present the blocking-data
fits (Fig. 4) and the prediction intervals based on these fits
(Fig. 6) without use of the blocking-efficiency concept.
However, this effect is subsequently explored when final
binding parameter estimates are made.
Prediction of nonblocked response is accurate
To provide a rigorous test of the concurrent binding model
(Zhu and Williams, 2000), a large number of micropipette
experiments were conducted under nonblocking conditions
using CD16b-transfected K562 cells against IgG-coated
RBCs at levels ranging from 650 down to 35 molecules of
IgG per m2. The kinetic-rate and binding-affinity con-
stants for CD16bNA2 and CD32aR/H131, derived from the
blocking data alone as described above (  1), were used
to generate prediction intervals for the mean response to
nonblocked binding, using Eq. 2 with all i set to zero.
Adhesion frequency data and prediction intervals for each
ligand-density level are shown in Fig. 6. The excellent
correspondence illustrates the strong predictive ability of
the model when applied to micropipette experiments. It also
suggests that the simplifying assumptions underlying the
concurrent binding model, most noticeably that of indepen-
dent binding, are valid for the system tested.
Best estimates of the binding parameters
Binding curves from both blocked and nonblocked condi-
tions were simultaneously fit to the concurrent binding
model (Eq. 2), with either a fixed  value of unity or
allowing it to vary as an additional freely-adjustable fitting
parameter. The resulting kinetic rate and binding affinity
constants are presented in Table 1, which show excellent
agreement with those estimated from fitting the blocked
data alone, imparting more confidence in the concurrent
binding model.
The data presented in Figs. 4 and 6 were collected from
a large number of experiments performed over the course of
several months using different preparations of cells and
reagents. As such, the standard errors generated by curve-
fitting the entire data set should include not only intra-
experimental variations of individual data points (e.g., cell-
to-cell variability in the same sample) but also inter-
experimental variations of individual subsets of data (e.g.,
variability among different preparations). This is in contrast
to standard errors generated by regressing data from only a
single experiment, which, in general, only account for intra-
experimental variations, and hence are often much smaller
than the standard errors calculated from multiple parameter
values, each of which is estimated from an individually
repeated experiment. Thus, the small standard errors shown
in Table 1 are indicative of both data quality and model
validity.
Although the reverse kinetic rates of the two receptors
were very similar in these data, the equilibrium binding
affinity of CD16bNA2 was greater than the affinity of
CD32aR/H131 by two- to threefold. This further confirms that
CD16b is the dominant player in the FcR–IgG-mediated
adhesion in the transfectant K652 cells.
FIGURE 5 Effects of blocking efficiency. If antibody blocking was
complete, the “no receptor” cases (Fig. 4 C) and the “no ligand” case (Fig.
4 D) would be the same. When antibody blocking efficiency was estimated
from the data, the mean blocking efficiency  was 94% and the single
solution in Fig. 4, C and D (shown here as the bold solid curve), became
three separate ones. Here, the best fit responses of the 6% of residual
receptors interacting with two coating densities of ligands, 580 IgG/m2
(E, dotted curve) and 650 IgG/m2 (F, thin solid curve), were distinctly
higher than that of the nonspecific “no ligand” case (Œ, dashed curve).
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DISCUSSION
A major goal of the present work was to quantify the
kinetics of FcR–IgG interactions. Like on neutrophils, the
CD16b on our K562 transfectants outnumbered the CD32a
by a factor of at least three. Possessing a substantially higher
2D affinity for IgG as well, CD16b played the dominant role
in Fc-mediated adhesion. The kinetic rate and binding af-
finity constants of CD32a for surface-bound ligand (i.e., the
so-called 2D binding parameters) have not been determined
previously. These parameters were measured in the present
study using the micropipette binding frequency assay. As
with the CD16bNA2–hIgG2 interaction described in Wil-
liams et al. (2000), the affinity of CD32aR/H131–hIgG bind-
ing is quite low. Both represent the weakest receptor–ligand
interactions for which 2D kinetic rates have ever been
successfully measured.
The special case of two receptor species binding the same
ligand species was examined to further test the validity of
concurrent binding model developed in Zhu and Williams
(2000). As in the case of two ligand species binding the
same receptor species (Williams et al., 2000), the approach
was to separate the data into two sets, using the results from
one set to predict the results from the other set. In this case,
results from sequential or simultaneous blocking of the two
FcRs coexpressed on CD16b-transfected K562 cells were
used to predict results from various nonblocked conditions.
Just as with the dual-ligand case, the experimental data
matched the prediction intervals extremely well, providing
substantial support for the concurrent binding model.
For purposes of comparing the association of two recep-
tors to a common ligand, the human IgG was treated as a
single uniform species. Total serum IgG consists of four
isotypes with differing proportions and binding parameters
for each FcR. Neutrophils encounter mixtures of all iso-
types, and, because it was not the objective of this work to
examine isotype-dependent behavior, treating the total se-
rum IgG as a homogeneous ligand provided a convenient
simplification (Zhu and Williams, 2000).
In the dual-ligand case examined in Williams et al.
(2000), the single-ligand binding was controlled by simply
not coating the unwanted ligand species onto the RBCs. By
comparison, in the present dual-receptor case the single-
receptor binding was achieved by using an adhesion-block-
ing mAb to inhibit the function of the unwanted receptor.
This represents a case of competitive binding between a
soluble mAb and a cell-bound ligand for the same cell
surface receptor. In a recent paper (Li et al., 1999), we
described a model for such competitive inhibition except
that, in the previous work, only a single receptor species
was present on the cell surface. A straightforward extension
of the model of Li et al. (1999) along the lines of reasoning
as in Zhu and Williams (2000) would allow it to be appli-
cable to the present case. Indeed, the effect of competition
by the soluble mAb is fully described by the simple concept
of blocking efficiency used in Eq. 2. Comparing Eq. 2 to the





where c is the volume concentration of the blocking mAb,
and Ka,3D is the three-dimensional (3D) binding affinity of
the fluid-phase mAb for the cell surface antigen (i.e., FcR).
In fact, the nearly complete blocking efficiency (  94 
3%) by specific antibodies is predicted by Eq. 3. For exam-
ple, using Ka,3D  8.3  10
7 M1 for CLBFcgran1 Fab–
CD16bNA2 interaction (Chesla et al., 2000) and the concen-
FIGURE 6 Nonblocked binding curves and prediction intervals. The adhesion of CD16b-transfected K562 cells was assayed against RBCs coated at
ligand densities of (A) 650, (B) 580, (C) 155, and (D) 35 molecules of IgG per m2. Each point (E) represents a single cell pair with 100 contact cycles
each. The solid lines were produced from the best-fit binding parameters extracted from the entire nonblocked data set. The 95% prediction intervals for
the mean response (shaded regions), computed from blocking data alone, correspond well with the nonblocked best-fit curves.
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tration (c  2  107 M) of CLBFcgran1 Fab used in the
blocking experiment, a  of 94.3% can be calculated from
Eq. 3. Similarly, the control experiment with irrelevant
antibodies is also a competition binding case. But the sol-
uble competitors are of much lower Ka,3D because here it is
the Fc binding rather than Fab binding. The negligible
blocking effect seen in Fig. 3 B is also predicted by Eq. 3,
based on the low affinities for soluble IgG of the two FcRs
(e.g., Ka,3D 2 and 3 10
4 M1 for CD16bNA2 interacting
with Fc of human and rabbit IgGs, Chesla et al., 2000) and
the concentration of mIgG Fc used in the control experiment
(c  6.7  108 M).
Although CD32a is found on most leukocytes, it is con-
stitutively coexpressed with CD16b only on neutrophils.
Here there is evidence for cooperative interaction between
these two FcRs in the generation of calcium transients and
the initiation of phagocytosis (Naziruddin et al. 1992; Ed-
berg and Kimberly 1994; Edberg et al. 1998). Simultaneous
cross-linking of both receptors, with either aggregated IgG
or antireceptor antibody, generates a substantially stronger
response than the sum of the responses to cross-linking of
each receptor species separately. The assumptions of the
concurrent binding model do not exclude synergy in these
types of downstream effector functions. But they do pre-
clude cooperation between the two receptor species that
would result in synergy in ligand binding kinetics, or
changes in receptor expressions. The high degree of corre-
spondence between the nonblocked data and the prediction
intervals derived from the blocked data suggests that the
noncooperative assumption has adequately accounted for
the binding kinetics of CD16b and CD32a when they are
coexpressed on K562 cells. If saturation binding of one
receptor by soluble antibody resulted in increased binding
of the other receptor, the prediction intervals (based on such
antibody treatment) for the untreated conditions would have
been too high. This was not the case here.
Similarly, in the nonblocked experiment, both CD16b
and CD32a were involved in the IgG-mediated adhesion.
By comparison, in the blocked experiment, only one recep-
tor was allowed to participate in the binding of cell-bound
IgG ligands. Should IgG binding via both FcRs have a
synergetic effect, the prediction intervals would have been
too low. Again, this was not seen here. A limited number of
bonds likely formed during each period of contact, which
itself endured for 16 s at most. However, the process was
repeated many times as each cell pair was subjected to a
series of 100 similar contacts, with cumulative contact pe-
riods of as much as 30 min. Adhesion frequency near the
end of each series did not show any consistent difference
from the frequency near the beginning (data not shown).
Additional evidence against the cross-FcR affinity reg-
ulation hypothesis in our system comes from the agreement
in the kinetic rates of CD16bNA2 when expressed on K562
cells (the present work) or Chinese hamster ovary (CHO)
cells (Williams et al., 2000). CHO cells do not express
CD32a, yet the CD16b kinetic rates obtained from that
system (AcKa  3.3  10
7 m4, kr  0.56 s
1) were
strikingly similar to their K562 cell counterparts (AcKa 
4.1  107 m4, kr  0.50 s
1, see Table 1).
In this work, we have provided evidence that saturation
binding of adhesion-blocking mAb to either CD16b or
CD32a does not alter the ligand affinity of the other receptor
when both are present on K562 cells. We similarly reject
affinity-level cooperation in our model system when both
receptors are allowed to concurrently bind to IgG. This is an
important initial step in understanding cross-talk between
these two molecules and in determining if and how the
downstream interactions observed in neutrophils relate to
their function as Fc adhesion receptors. Additional work is
immediately suggested. It is likely that a portion of the
mAb-bound receptors were also cross-linked when divalent
whole mAb was used for adhesion blocking, so the simi-
larity with the monovalent Fab blocking results (Fig. 3 A)
implies that such intraspecies cross-linking did not stimulate
any ligand affinity regulation. However, we have left unex-
plored the possible outcomes of interspecies cross-linking
(i.e., CD16b–CD32a).
This work used CD16b-transfected K562 cells as a po-
tential model for neutrophil FcR functions. Our transfec-
tant K562 is the only immortalized cell line that coexpresses
both CD16b and CD32a. Furthermore, the relative expres-
sion levels of the two FcRs are similar for both neutrophils
and our transfectants. The availability of a perpetual supply
of genetically uniform model cells offers clear advantages,
and it is our hope that results derived from the K562
transfectants will provide a useful complement to direct
neutrophil studies. Functional comparisons of both adhesion
and signaling behavior in the two cells will be particularly
critical. For example, if affinity cross-regulation can be
demonstrated on the neutrophil, then the lack of such cross-
talk in the K562 model would suggest the action of an
intermediate agent, identification of which would be aided
by its apparent absence on the K562 cells. The concurrent
binding model and blocking approach presented in this
report provide a good foundation for these studies. Such
studies will help us to define the physiological significance
of coexpressing different receptors with overlapping ligand
specificity.
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